Atossa Genetics (ATOS) News Today $0.77 +0.01 (+1.47%) As of 03:31 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock ATOS Latest News All Sources Trusted Sources MarketBeat Barchart Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent August 2025 July 2025 June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 Time Period Atossa Genetics (NASDAQ:ATOS) Share Price Passes Above 200 Day Moving Average - What's Next?August 22, 2025 | marketbeat.comAtossa Therapeutics Selects PSI as Contract Research Organization for Pivotal Dose-Ranging Study of (Z)-Endoxifen in Metastatic Breast CancerAugust 20, 2025 | prnewswire.comAnalysts Set Expectations for Atossa Genetics Q3 EarningsAugust 17, 2025 | marketbeat.comHC Wainwright Expects Reduced Earnings for Atossa GeneticsAugust 16, 2025 | americanbankingnews.comAtossa Genetics (NASDAQ:ATOS) Issues Earnings ResultsAugust 13, 2025 | marketbeat.comAtossa Genetics (NASDAQ:ATOS) Stock Price Passes Below 200 Day Moving Average - Time to Sell?August 13, 2025 | marketbeat.comAtossa Therapeutics Announces Second Quarter 2025 Financial Results and Provides a Corporate UpdateAugust 12, 2025 | prnewswire.comAtossa Genetics (ATOS) to Release Quarterly Earnings on MondayAugust 5, 2025 | marketbeat.comAtossa Genetics (NASDAQ:ATOS) Stock Price Crosses Above Two Hundred Day Moving Average - Here's What HappenedAugust 3, 2025 | marketbeat.comAtossa Therapeutics and Calidi Biotherapeutics Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TVAugust 1, 2025 | finance.yahoo.comAtossa Therapeutics Announces Positive FDA Feedback, Advances Toward IND for (Z)-Endoxifen Clinical Program in ER+/HER2- Metastatic Breast CancerJuly 29, 2025 | prnewswire.comAtossa Genetics (NASDAQ:ATOS) Shares Cross Above 200-Day Moving Average - Here's WhyJuly 26, 2025 | marketbeat.comAtossa Therapeutics (NASDAQ:ATOS) Given New $7.50 Price Target at Ascendiant Capital MarketsJune 6, 2025 | marketbeat.comCraig-Hallum Initiates Coverage of Atossa Therapeutics (ATOS) with Buy RecommendationJune 6, 2025 | msn.comCraig Hallum Begins Coverage on Atossa Therapeutics (NASDAQ:ATOS)June 5, 2025 | marketbeat.comAtossa Therapeutics to Present at the Jefferies Global Healthcare ConferenceJune 2, 2025 | prnewswire.comAtossa Therapeutics Reports Q1 2025 Financial ResultsMay 27, 2025 | tipranks.comAtossa Therapeutics (NASDAQ:ATOS) Stock Price Passes Above 200-Day Moving Average - Time to Sell?May 24, 2025 | marketbeat.comAtossa Therapeutics CEO Steven Quay buys $9,886 in common stockMay 24, 2025 | investing.comAtossa Therapeutics, Inc.: Join Atossa Therapeutics' Exclusive Live Investor Webinar and Q&A Session on May 22May 20, 2025 | finanznachrichten.deAtossa Therapeutics (NASDAQ:ATOS) Issues Earnings ResultsMay 15, 2025 | marketbeat.comAtossa Therapeutics (NASDAQ:ATOS) Stock Crosses Below 200-Day Moving Average - Here's WhyMay 15, 2025 | marketbeat.comAtossa Therapeutics Inc: Atossa Therapeutics Announces Full Results from I-SPY 2 Endocrine-Optimization Sub-Study Evaluating Low-Dose (Z)-EndoxifenMay 14, 2025 | finanznachrichten.deAtossa Therapeutics Announces Full Results from I‑SPY 2 Endocrine‑Optimization Sub‑Study Evaluating Low‑Dose (Z)‑EndoxifenMay 14, 2025 | finance.yahoo.comAtossa Therapeutics Announces Full Results from I‑SPY 2 Endocrine‑Optimization Sub‑Study Evaluating Low‑Dose (Z)‑EndoxifenMay 14, 2025 | prnewswire.comAtossa Therapeutics Inc: Atossa Therapeutics Announces First Quarter 2025 Financial Results and Provides a Corporate UpdateMay 13, 2025 | finanznachrichten.deAtossa Therapeutics Announces First Quarter 2025 Financial Results and Provides a Corporate UpdateMay 13, 2025 | prnewswire.comAtossa Therapeutics (ATOS) to Release Quarterly Earnings on MondayMay 7, 2025 | marketbeat.comAtossa Therapeutics Announces Issuance of U.S. Patent No. 12,281,056, Including 58 Claims Covering Various Formulations for its (Z)-endoxifen PortfolioApril 30, 2025 | globenewswire.comAtossa Therapeutics Proposes Potentially Groundbreaking Study Aimed at Reducing Interval Breast Cancer in High-Risk Women at AACR 2025April 29, 2025 | finance.yahoo.comAtossa Therapeutics Proposes Potentially Groundbreaking Study Aimed at Reducing Interval Breast Cancer in High-Risk Women at AACR 2025April 29, 2025 | globenewswire.comAscendiant Capital Markets Predicts ATOS Q1 EarningsApril 25, 2025 | marketbeat.comAtossa Therapeutics secures new patent for breast cancer treatmentApril 24, 2025 | uk.investing.comPRISM Mid-Day Movers: Board Shakeups and Biotech Financings Drive Investor FocusApril 23, 2025 | theglobeandmail.comAtossa Therapeutics announces issuance of U.S. patentApril 23, 2025 | markets.businessinsider.comAtossa Therapeutics (NASDAQ:ATOS) Given New $7.25 Price Target at Ascendiant Capital MarketsApril 23, 2025 | marketbeat.comAtossa Therapeutics Announces Issuance of U.S. Patent No. 12,275,684, Further Strengthening (Z)-endoxifen PortfolioApril 22, 2025 | globenewswire.comNona Biosciences Inks Research Partnership With Atossa Therapeutics For Next-gen Breast Cancer DrugsApril 12, 2025 | nasdaq.comAtossa Therapeutics and Nona Biosciences partner in breast cancer antibodiesApril 11, 2025 | markets.businessinsider.comNona Biosciences, Atossa Partner on Next-Gen Breast Cancer Antibody TherapiesApril 11, 2025 | msn.comNona Biosciences and Atossa Therapeutics Partner to Discover Next-Generation Antibody Therapies for Breast CancerApril 10, 2025 | prnewswire.comAtossa Therapeutics (ATOS) Projected to Post Quarterly Earnings on MondayMarch 31, 2025 | marketbeat.comQ1 EPS Forecast for Atossa Therapeutics Boosted by AnalystMarch 29, 2025 | marketbeat.comAtossa Therapeutics’ Earnings Call Highlights Cost Reductions and Clinical ProgressMarch 28, 2025 | tipranks.comAtossa Therapeutics (NASDAQ:ATOS) Receives Buy Rating from HC WainwrightMarch 27, 2025 | marketbeat.comAtossa Therapeutics, Inc. (ATOS) Q4 2024 Earnings Call TranscriptMarch 27, 2025 | seekingalpha.comAtossa Therapeutics reports Q4 EPS (20c), consensus (22c)March 27, 2025 | markets.businessinsider.comQ4 2024 Atossa Therapeutics Inc Earnings CallMarch 26, 2025 | uk.finance.yahoo.comWe Think Atossa Therapeutics (NASDAQ:ATOS) Can Afford To Drive Business GrowthMarch 26, 2025 | finance.yahoo.comAtossa Therapeutics (NASDAQ:ATOS) Releases Quarterly Earnings Results, Beats Estimates By $0.01 EPSMarch 26, 2025 | marketbeat.com Get Atossa Genetics News Delivered to You Automatically Sign up to receive the latest news and ratings for ATOS and its competitors with MarketBeat's FREE daily newsletter. Email Address ATOS Media Mentions By Week ATOS Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. ATOS News Sentiment▼0.580.70▲Average Medical News Sentiment ATOS News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. ATOS Articles This Week▼22▲ATOS Articles Average Week Get Atossa Genetics News Delivered to You Automatically Sign up to receive the latest news and ratings for ATOS and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies IMAB News YMAB News ATXS News VIGL News NBTX News OLMA News FULC News ABEO News CAPR News ZYBT News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:ATOS) was last updated on 8/26/2025 by MarketBeat.com Staff From Our Partners“Sell Nvidia before earnings”Eric Fry just went live with one of his most controversial calls yet: “Sell Nvidia.” While Wall Street has bee...InvestorPlace | SponsoredWhat Steve Bannon revealed about Trump’s gold playA Trump advisor just said 3 words that could reset the dollar. It’s a gold move nobody saw coming—and your ...Reagan Gold Group | SponsoredThe stealth altcoin the financial world is underestimatingThis DeFi project could soar next When altcoin season fully kicks in—which the data suggests is happening R...Crypto 101 Media | SponsoredThink you missed gold’s boom? Think againIf you've been watching gold's historic run and wondering if it's too late… I've got good news. Because the...Investors Alley | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredFed Decision Warning: How to Protect Your Wealth Before September 30th On September 17th, the Fed faces an impossible choice—and Wall Street insiders are already preparing for the...American Alternative | SponsoredElon’s BIGGEST warning yet?Tesla's About to Prove Everyone Wrong... Again Back in 2018, when Jeff Brown told everyone to buy Tesla… ...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Atossa Genetics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Atossa Genetics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access